ALL NEWS

5450 RESULTS

Sort By:

Alzheimer's Association International Conference 2019

New PET Staging Scheme for Amyloid? Physical Activity May Shield the Brain from the Onslaught of Aβ Crenezumab Update: Baseline Data from Colombian Prevention Trial Colombian Cohort Delivers Data on Blood NfL Rare Luck: Two Copies of ApoE2 Shield Against ...

Results of Ladostigil Trial Published

The Phase 2 study missed its primary endpoint. While fewer developed dementia in the treatment group, the effect was not statistically significant. People on drug had less brain atrophy than those on placebo.

Stress and Alzheimer’s Disease

With the holidays upon us, are your nerves fraying under the combined pressures of work deadlines, shopping, decorating, and entertaining? Now may be a good time to sit back and consider the effects of stress on the brain. Stress per se is not a cause of ...

Brain Training—Plain Gaming, or a New Vein for Preclinical Research?

If you listen to National Public Radio, watch TV, or surf the Web, chances are you have come across commercials enticing you to “improve your memory” and “unlock your inner genius” with “brain training developed by neuroscientists.”  In search of solid ...

CRISPR: A New Tool For Gene Editors

CRISPR Gene Editing—Poised to Revolutionize Neuroscience? Neuroscientists Probe CRISPR Transgenics and Treatment Paradigms ...

DIAN: International Network to Chart AD Preclinical Decade

The rarest kind of Alzheimer's disease, the form that is inherited from parent to child with a cruel 50 percent likelihood, has long been marked by its untapped opportunities. Affected families have made possible both the discovery of the first three ...

Update on DIAN, API, A4: All About Biomarkers, Trials, and Funds

Alzforum readers who follow the science of preclinical Alzheimer's and prevention may have heard about three independent but complementary programs that together are laying the groundwork for secondary prevention trials across the spectrum of rare to ...

Guidelines Bring Needed Change, Though Not Enough for Some

U.S. guidelines for assessing Alzheimer's disease (AD) neuropathology are getting a much-needed facelift. The existing ones, in place since 1997, had fallen out of step with the current understanding of AD as a disease with a long preclinical stage. ...

Current Filters

  • Date Range : All x

Remove all filters

Filter By

DATE RANGE
  • All
  • Past 7 Days
  • Past 30 Days
  • Past 90 Days
  • Past 12 Months
  • Specific Dates
    1. From
      To

TYPE OF NEWS
DISEASE
TOPIC
BIOMOLECULE